ArticleCells2026
Integrated Pharmacogenomic and Structure-Guided Analyses Link LCC-10 (NSC765599) to an MMP-Associated Extracellular Matrix Regulatory Network in Leukemia.
Han-Lin Hsu, Tawakalitu Bidemi Aliu, Ya-Ting Wen, Yu-Cheng Kuo, Li Wei, Ruey-Shyang Soong, Maryam Rachmawati Sumitra, Sheng-Liang Huang, Shih-Yu Lee, Sung-Ling Tang and 6 more
Abstract read
In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Han-Lin HsuGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Tawakalitu Bidemi AliuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Ya-Ting WenDivision of Neurosurgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 10608, Taiwan.
Yu-Cheng KuoDepartment of Pharmacology, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0003-1344-6098 Li WeiDivision of Neurosurgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei 10608, Taiwan.
Ruey-Shyang SoongDivision of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.
Maryam Rachmawati SumitraGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0009-0006-0097-7382 Sheng-Liang HuangGraduate Institute of Aerospace and Undersea Medicine, National Defense Medical University, Taipei 11490, Taiwan.
Shih-Yu LeeGraduate Institute of Aerospace and Undersea Medicine, National Defense Medical University, Taipei 11490, Taiwan.ORCID 0000-0002-4713-6410 Sung-Ling TangSchool of Pharmacy, National Defense Medical University, Taipei 11490, Taiwan.
I-Chuan YenSchool of Pharmacy, National Defense Medical University, Taipei 11490, Taiwan.
George HsiaoDepartment of Pharmacology, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-9079-3646 Alexander T H WuThe Ph.D. Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-0178-6530 Hsu-Shan HuangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-6193-5182 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Leukemia progression is increasingly shaped by reciprocal interactions between leukemic cells and the bone marrow microenvironment, yet the extracellular regulatory networks associated with these interactions remain incompletely understood. Here, we investigated the biological context associated with the antileukemic activity of LCC-10 (NSC765599), a synthetic biphenyl benzamide derivative, using an integrated pharmacogenomic and structure-guided computational framework. Antiproliferative activity was first characterized using the NCI-60 screen and subsequently integrated with pharmacogenomic response similarity analysis, baseline transcriptomic profiling, similarity-based target prediction, systems-level network analysis, molecular docking, coarse-grained molecular dynamics simulations, comparative in silico ADMET evaluation, and zebrafish embryo developmental toxicity assessment. LCC-10 exhibited potent antiproliferative activity across leukemia cell lines, with submicromolar GI
Indexed as
BenzamidesExtracellular MatrixLeukemiaMatrix MetalloproteinasesPharmacogeneticsAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Molecular Docking SimulationMolecular Dynamics SimulationZebrafishAntineoplastic AgentsBenzamidesMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix Metalloproteinasesbone marrow microenvironmentextracellular matrixleukemiamatrix metalloproteinasespharmacogenomicssystems pharmacology
Identifiers
PMID42738903
PMCPMC13564721
What OpenQuestion holds
Textmetadata
Read underepoch 390